Mercia Asset Management PLC Investment into OXGENE
06 Mayo 2020 - 1:00AM
RNS Non-Regulatory
TIDMMERC
Mercia Asset Management PLC
06 May 2020
RNS Reach 6 May 2020
Mercia Asset Management PLC
("Mercia", the "Company" or the "Group")
Mercia invests GBP1.0million as part of a GBP3.0million
syndicated investment into OXGENE (TM)
Mercia Asset Management PLC (AIM: MERC), the proactive,
regionally focused specialist asset manager, is pleased to announce
that it has completed a GBP1.0million investment into OXGENE(TM)
("OXGENE(TM)" is the trading name of Oxford Genetics Limited) as
part of a GBP3.0million funding commitment, alongside Canaccord
Genuity Wealth Management.
OXGENE(TM) combines precision engineering, biology, robotics and
bioinformatics to accelerate the design, discovery and manufacture
of new biologics. Working across the fields of gene therapy, gene
editing and antibody therapeutics, OXGENE(TM) has worked with
global partners including Abcam plc for the delivery of over 1,000
CRISPR engineered cell lines, Artios Pharma, who are developing
breakthrough cancer treatments, and The Native Antigen Company
(also a Mercia direct investment) to accelerate the production of
COVID-19 antigens.
In addition, OXGENE(TM) has signed eight separate licence
agreements providing access to its technology and recently
announced a strategic partnership with FUJIFILM Diosynth
Biotechnologies, a world leading cGMP contract development and
manufacturing organisation, to support its partners in the
development and production of biologics, vaccines and gene
therapies.
The synthetic biology market in which OXGENE(TM) operates is
estimated to grow from US$5.3billion in 2019 to US$18.9billion by
2024. (Source: BCC Research)
Jo Bath, Chief Operations Officer of OXGENE (TM) , said:
"Over the course of this financial year, OXGENE(TM) has once
again more than doubled its revenue, with less than a 50% increase
in headcount. This is testament not only to the hard work and
effective management of our team, but also to the strength of our
automation platform, and our focused approach to business and
technology development.
Mercia has continued to support and encourage us through this
year of growth and transition. Their support goes beyond financial,
helping us navigate through challenges as they arise. We're
extremely proud of everything we've accomplished this year, and
look forward to bringing more innovative, game changing
technologies to market in the year ahead."
Mark Payton , Chief Executive Officer of Mercia, commented :
" OXGENE(TM) is now being repeatedly recognised by some of the
world's largest pharmaceutical brands which see the considerable
value of its proprietary technology. The company is rapidly
addressing global healthcare challenges and this latest investment
round demonstrates the confidence that Mercia has in the business
and its management team to deliver medium to long-term value."
Ends
For further information, please contact:
Mercia Asset Management PLC
Mark Payton, Chief Executive Officer
Martin Glanfield, Chief Financial Officer +44 (0)330 223
www.mercia.co.uk 1430
Canaccord Genuity Limited (NOMAD and Joint +44 (0)20 7523
Broker) 8000
Simon Bridges, Richard Andrews
N+1 Singer (Joint Broker)
+44 (0)20 7496
Harry Gooden, James Moat 3000
+44 (0)20 3727
FTI Consulting 1051
Tom Blackwell, Louisa Feltes, Antonia Powell
mercia@fticonsulting.com
About Mercia Asset Management PLC
Mercia is a proactive, specialist asset manager focused on
supporting regional SMEs to achieve their growth aspirations.
Mercia provides capital across its four asset classes of balance
sheet, venture, private equity and debt capital: the Group's
'Complete Connected Capital'. The Group initially nurtures
businesses via its third-party funds under management, then over
time Mercia can provide further funding to the most promising
companies, by deploying direct investment follow-on capital from
its own balance sheet.
The Group has a strong UK regional footprint through its eight
offices, 19 university partnerships and extensive personal
networks, providing it with access to high-quality deal flow.
Mercia currently has c.GBP800million of assets under management
and, since its IPO in December 2014, has invested over GBP90million
across its direct investment portfolio.
Mercia Asset Management PLC is quoted on AIM with the epic
"MERC".
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKKPBNFBKDDPK
(END) Dow Jones Newswires
May 06, 2020 02:00 ET (06:00 GMT)
Mercia Asset Management (LSE:MERC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Mercia Asset Management (LSE:MERC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024